Johnson Fistel Announces Class Action Lawsuit Against Lantheus Holdings, Inc. (LNTH) on Behalf of Investors

(NasdaqGM:LNTH), DENVER, Oct. 17, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Lantheus Holdings, Inc. (NASDAQ: LNTH). The lawsuit seeks to recover losses on behalf of investors who purchased the Company's securities between February 26, 2025 and August 5, 2025, inclusive (the “Class […]

Gene Siskel Film Center of the School of the Art Institute of Chicago Announces Full Program for the 31st Annual Black Harvest Film Festival

Festival lineup includes eight feature films and nine shorts, film awards, a Community Film Workshop, Mystery Movie Monday, and BLKNWS The GeneSiskel Film Centerof the School of the Art Institute of Chicago proudly announces the full lineup for the 31st Annual Black Harvest Film Festival, Chicago's annual showcase for Black cinema from across the diaspora.

All About Bail Bonds Expands Presence to Serve Houston Families

All About Bail Bonds, one of Houston's most trusted names in bail bonding, proudly announces the expansion to Houston's Southside All About Bail Bonds, one of the most trusted names in bail bond services, proudly announces their expansion to Houston's Southside, a full-service office now opens at 3936 Old Spanish Trail, Suite B, 77021. This

Johnson Fistel Announces Class Action Lawsuit Against Lantheus Holdings, Inc. (LNTH) on Behalf of Investors

Johnson Fistel Announces Class Action Lawsuit Against Lantheus Holdings, Inc. (LNTH) on Behalf of Investors GlobeNewswire October 17, 2025 DENVER, Oct. 17, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Lantheus Holdings, Inc. (NASDAQ: LNTH). The lawsuit seeks to recover losses on behalf

V.F. Corporation (VFC) Class Action Lawsuit Announced by Johnson Fistel

(NYSE:VFC), SAN DIEGO, Oct. 17, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP's Denver office announces that a class action lawsuit has been filed on behalf of investors who purchased V.F. Corporation (NYSE: VFC) securities between October 30, 2023, and May 20, 2025. Investors who suffered losses during this period may be eligible for compensation. Eligibility

V.F. Corporation (VFC) Class Action Lawsuit Announced by Johnson Fistel

V.F. Corporation (VFC) Class Action Lawsuit Announced by Johnson Fistel GlobeNewswire October 17, 2025 SAN DIEGO, Oct. 17, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP's Denver office announces that a class action lawsuit has been filed on behalf of investors who purchased V.F. Corporation (NYSE: VFC) securities between October 30, 2023, and May 20, 2025.

METROCITY BANKSHARES, INC. REPORTS EARNINGS FOR THIRD QUARTER 2025

MetroCity Bankshares, Inc. (“MetroCity” or the “Company”) (NASDAQ: MCBS), holding company for Metro City Bank (the “Bank”), today reported net income of $17.3 million, or $0.67 per diluted share, for the third quarter of 2025, compared to $16.8 million, or $0.65 per diluted share, for the second quarter of 2025, and $16.7 million, or $0.65

Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals Results support the potential advancement of ART6043 into Phase 2 clinical development CAMBRIDGE, United Kingdom and NEW YORK, October 17, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the

Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025

Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025 GlobeNewswire October 17, 2025 Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals Results support the potential advancement of ART6043 into Phase 2 clinical development CAMBRIDGE, United

Scroll to Top